NCT01496170View on ClinicalTrials.gov

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Alzheimer's Disease
Interventions
DRUG

MK-8931

MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days

DRUG

Placebo

Placebo capsules, orally, once per day for 7 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01496170 - A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1]) | Biotech Hunter | Biotech Hunter